Blackrock's Clinical Distribution Advantage

This is a go to market advantage, not just a research credential. Blackrock has spent years selling hardware into university labs, neurosurgery teams, and rehabilitation researchers, so when it moves from experiments to a product, it already knows the hospitals, principal investigators, and clinical workflows that decide who gets implanted, who trains patients, and who publishes the first outcome data. Neuralink still has to assemble much of that network while also building its own specialized surgical path.

• Blackrock's installed base matters because NeuroPort has been used in human BCI work since 2004 and published in more than 1,000 peer reviewed articles. That creates a ready pool of surgeons, lab staff, and institutions already trained on its hardware and data systems.
  2 blackrockneurotech 3 blackrockneurotech
• The Utah Array came out of the University of Utah ecosystem, and Blackrock remains tightly linked to that academic network. That history helped make its devices standard tools for IRB approved human studies, which is often how new neurotech spreads from one medical center to the next.
  3 blackrockneurotech 4 utah 6 blackrockneurotech
• Neuralink is taking a more vertically integrated route. Its system depends on custom threads, custom chips, and a surgical robot, which can improve performance but narrows the number of hospitals that can adopt it early because sites need new training, new procedures, and likely new capital equipment.
  5 sacra 7 sacra

The next phase of BCI commercialization will be shaped as much by hospital adoption mechanics as by decoding performance. Companies with existing academic and clinical footholds can spread center by center through familiar research and care pathways, while Neuralink's upside depends on turning its superior interface into a repeatable procedure that many hospitals can actually deliver.